Rakhi P. Naik

Rakhi P. Naik

Auto-generated profile, based on publicly available information

Rakhi P. Naik

Division of Hematology, Department of Medicine Johns Hopkins University Baltimore Maryland USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2014 in JAMA
Verified
Journal Article
Open access
PDF file
RNRakhi P. Naik
Rakhi P. Naik
VDVimal K. Derebail
Vimal K. Derebail
MGMorgan E. Grams
Morgan E. Grams
NFNora Franceschini
Nora Franceschini
PAPaul L. Auer
Paul L. Auer
ARAlexander P. Reiner
Alexander P. Reiner
Sickle cell trait (SCT) is defined as inheritance of a single copy of the sickle mutation that results from a single base pair substitution in the gene encoding the β-globin chain of hemoglobin. It is estimated that SCT affects 1 in 12 African Americans and nearly 300 million people worldwide.1,2

1 May 2013 in The American Journal of Medicine
Verified
Journal Article
Closed access
RNRakhi P. Naik
Rakhi P. Naik
MSMichael B. Streiff
Michael B. Streiff
CHCarlton Haywood
Carlton Haywood
JNJulie A. Nelson
Julie A. Nelson
SLSophie Lanzkron
Sophie Lanzkron

3 October 2014 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
RNR. P. Naik
R. P. Naik
MSM. B. Streiff
M. B. Streiff
CHC. Haywood
C. Haywood
JSJ. B. Segal
J. B. Segal
SLS. Lanzkron
S. Lanzkron
Background Venous thromboembolism (VTE) has been recently recognized as a complication of sickle cell disease (SCD); however, the incidence of VTE in SCD is unknown. Objectives The primary objective of this study was to determine the incidence of first VTE, including pulmonary embolism (PE) and deep vein thrombosis (DVT), among SCD patients age ≥ 15 years. We also evaluated genotypic differences in VTE risk and determined the relationship between VTE and mortality. Patients/methods In this retrospective cohort study, we used data from the Cooperative Study of Sickle Cell Disease (CSSCD) to calculate incidence rates for first VTE. We used Cox proportional hazard models to estimate hazard ratios (HRs) for time to VTE by genotype and time to death by VTE status. Results We included 1523 SCD patients aged ≥ 15 years with 8862 years of follow‐up in this analysis. The incidence rate for first VTE was 5.2 events/1000 person‐years (95% confidence interval [CI] 3.8–6.9) with a cumulative incidence of 11.3% (95% CI 8.3–15.3) by age 40 years. Individuals with the SS/Sβ0‐thalassemia genotype had the highest rate of VTE (7.6 events/1000 person‐years [95% CI 5.3–10.6]). The incidence of PE exceeded that of isolated DVT (3.6 [95% CI 2.5–5.1] events/1000 person‐years vs. 1.6 [95% CI 0.9–2.7] events/1000 person‐years), although this difference was not statistically significant. SCD patients with VTE had a higher mortality rate (adjusted HR 2.32 [95% CI 1.20–4.46]) than those without VTE. Conclusions Patients with SCD are at substantial risk for VTE, and individuals with VTE are at higher risk of death than those without VTE.

5 December 2015 in Hematology-American Society Hematology Education Program
Verified
Journal Article
Open access
PDF file
RNRakhi P. Naik
Rakhi P. Naik
CHCarlton Haywood
Carlton Haywood
The sickle hemoglobin (HbS) point mutation has independently undergone evolutionary selection at least five times in the world because of its overwhelming malarial protective effects in the heterozygous state. In 1949, homozygous Hb S or sickle cell disease (SCD) became the first inherited condition identified at the molecular level; however, since then, both SCD and heterozygous Hb S, sickle cell trait (SCT), have endured a long and complicated history. Hasty adoption of early mass screening programs for SCD, recent implementation of targeted screening mandates for SCT in athletics, and concerns about stigmatization have evoked considerable controversy regarding research and policy decisions for SCT. Although SCT is a largely protective condition in the context of malaria, clinical sequelae, such as exercise-related injury, renal complications, and venous thromboembolism can occur in affected carriers. The historical background of SCD and SCT has provided lessons about how research should be conducted in the modern era to minimize stigmatization, optimize study conclusions, and inform genetic counseling and policy decisions for SCT.

24 February 2013 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
RNRakhi P. Naik
Rakhi P. Naik
MSMichael B. Streiff
Michael B. Streiff
SLSophie Lanzkron
Sophie Lanzkron

9 March 2017 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
RNRakhi P. Naik
Rakhi P. Naik
MIMarguerite R. Irvin
Marguerite R. Irvin
SJSuzanne Judd
Suzanne Judd
OGOrlando M. Gutiérrez
Orlando M. Gutiérrez
NZNeil A. Zakai
Neil A. Zakai
MCMary Cushman
Mary Cushman
Blacks, compared with whites, have an increased risk of progression to end-stage renal disease (ESRD). Emerging evidence suggests that, in addition to APOL1 high-risk genotypes, hemoglobin variants, including sickle cell trait (SCT) and hemoglobin C trait, have a role in kidney disease in blacks. However, the association between these hemoglobin traits and ESRD remains unknown. In a large population-based cohort, the REasons for Geographic and Racial Differences in Stroke (REGARDS) study, we evaluated 9909 self-reported blacks (739 with SCT and 243 with hemoglobin C trait). Incident ESRD occurred in 40 of 739 (5.4%) individuals with SCT, six of 243 (2.5%) individuals with hemoglobin C trait, and 234 of 8927 (2.6%) noncarriers. The incidence rate for ESRD was 8.5 per 1000 person-years for participants with SCT and 4.0 per 1000 person-years for noncarriers. Compared with individuals without SCT, individuals with SCT had a hazard ratio for ESRD of 2.03 (95% confidence interval, 1.44 to 2.84). Hemoglobin C trait did not associate with prevalent CKD or ESRD. The incidence rate for ESRD among participants with APOL1 high-risk genotypes was 6.6 per 1000 person-years, with a hazard ratio for ESRD of 1.77 (95% confidence interval, 1.31 to 2.38) for participants with, compared with those without, APOL1 high-risk genotypes. In this cohort, SCT strongly associated with risk of progression to ESRD in blacks, and this degree of risk for ESRD was similar to that conferred by APOL1 high-risk genotypes. These results may have important public policy implications for genetic counseling of SCT carriers.